Treatment of Core Binding Factor Acute Myelogenous Leukemia with Fludarabine, Cytarabine and Granulocyte Colony Stimulating Factor Results in Improved Event-Free Survival

Por Borthakur, Gautam, Kantarjian, Hagop, Wang, Xuemei, Plunkett, William K., Gandhi, Varsha V, Faderl, Stefan, Garcia-Manero, Guillermo, Ravandi, Farhad, Pierce, Sherry, Estey, Elihu H.
Publicado em 2008

A Phase I Study of Fludarabine, Cytarabine, and Oxaliplatin in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Por Tsimberidou, Apostolia-Maria, Keating, Michael J., Jabbour, Elias J, Ravandi-Kashani, Farhad, O'Brien, Susan, Estey, Elihu, Bekele, Neby, Plunkett, William K., Kantarjian, Hagop, Borthakur, Gautam
Publicado no Clin Lymphoma Myeloma Leuk (2014)

A phase I study of pemetrexed in patients with relapsed or refractory acute leukemia

Por Abdel-Karim, Isam, Plunkett, William K., O’Brien, Susan, Giles, Francis, Thomas, Deborah, Faderl, Stefan, Ravandi, Farhad, Rios, Mary Beth, Du, Min, Schneck, Karen B., Chen, Victor J., Lin, Boris K., Nicol, Steven J., Kantarjian, Hagop M.
Publicado em 2010